Brown Advisory Inc. Has $11.58 Million Stake in Sanofi (NASDAQ:SNY)

Brown Advisory Inc. increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 82.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,053 shares of the company's stock after acquiring an additional 108,239 shares during the quarter. Brown Advisory Inc.'s holdings in Sanofi were worth $11,578,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of SNY. Synergy Asset Management LLC bought a new position in shares of Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after acquiring an additional 543 shares in the last quarter. Bessemer Group Inc. grew its stake in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares during the period. Lee Danner & Bass Inc. bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $31,000. Finally, Sierra Ocean LLC bought a new stake in shares of Sanofi during the fourth quarter valued at approximately $44,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $53.15 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $134.27 billion, a PE ratio of 21.35, a PEG ratio of 1.01 and a beta of 0.55. The stock's 50 day moving average price is $54.51 and its 200-day moving average price is $52.04. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business's revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.78 EPS. On average, equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a $2.0369 dividend. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's payout ratio is presently 57.14%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.